Dyadic (AMEX:DIL)
Historical Stock Chart
From Jul 2019 to Jul 2024
Dyadic International, Inc. (AMEX:DIL), a biotechnology
company, announced today that Glenn E. Nedwin, Ph.D., MBA, co-founder
and President since 1991 of Novozymes, Inc., has been appointed to the
positions of Chief Scientific Officer, Executive Vice President and
President of Dyadic's Biosciences Business effective tomorrow, March
22, 2006. Dr. Nedwin also will join Dyadic's Board of Directors.
At Novozymes, Inc., a Davis, California-based research &
development subsidiary of Novozymes A/S (CSE:NZYMb.CO), Denmark, a
global leader in enzymes and microorganisms with over $1 billion in
worldwide revenues, Dr. Nedwin was responsible for all scientific,
financial and administrative activities, and was a member of Novozymes
A/S global R&D management team and its biosolutions strategy group,
and was involved in technology/product licensing. From 1989 to 1991,
Dr. Nedwin served as Vice President of Corporate Development, Xoma
Corporation (NASDAQ:XOMA), a biotechnology company based in Berkeley,
California. Earlier, he was Vice President, Business Development and
co-founder of Ideon Corporation, Redwood City, California, and Senior
Research Scientist and co-founder of Molecular Therapeutic, Inc. (now
Bayer Pharmaceuticals Corporation), West Haven, Connecticut.
"Glenn Nedwin is a biotechnology pioneer and visionary with more
than 24 years of leadership experience and an unparalleled record of
accomplishments in both the scientific and business aspects of our
industry," said Mark Emalfarb, President and CEO of Dyadic. "We are
thrilled that he has agreed to join Dyadic, and look forward to his
contributions to the development and commercialization of our
proprietary bio-based products. Glenn's success in identifying new
product opportunities and developing and utilizing microbial host
production organisms for the large scale production of enzymes and
other bio-based molecules will be invaluable resources for Dyadic as
we strive to achieve our growth objectives and build value for our
shareholders."
As Dyadic's Chief Scientific Officer, Dr. Nedwin will direct
scientific and development activities and oversee the planned
expansion of the company's R&D efforts. In his capacity as President
of the Biosciences Business, Dr. Nedwin will also be responsible for
strategic business development, partnering, alliances and
collaborative research relationships.
Dr. Nedwin commented, "I am excited by the opportunity to work
with Dyadic's seasoned management team, its world-renowned Scientific
Advisory Board and Board of Directors to maximize the potential of the
company's rich technology platform and established large-scale
manufacturing capabilities. Dyadic has quickly established itself as
an innovative manufacturer of industrial enzymes with its proprietary
C1 fungal strain for highly efficient protein production, a critical
factor for commercialization of industrial products. With the C1
genome sequence information now in hand, Dyadic's technology is well
suited to identify and produce new enzymes, polymers and chemicals
from carbohydrate sources. C1 can potentially be used to produce
enzymes involved in the production of cellulosic ethanol and other
chemicals from renewable feedstocks. Dyadic's C1 host is also
well-suited for low-cost production of monoclonal antibodies and other
therapeutic proteins. I look forward to the challenge of expanding
Dyadic's position in its existing industrial markets as well as
establishing new, higher value opportunities in biofuels and
pharmaceuticals."
Dr. Nedwin, 50, received his Bachelor of Science degree in
Biochemistry from the State University of New York at Buffalo and his
Ph.D. in Biochemistry from the University of California, Riverside.
Dr. Nedwin did his postdoctoral fellowship in molecular biology at
Genentech, Inc. Dr. Nedwin also holds an M.S. in the Management of
Technology from the Massachusetts Institute of Technology and is
currently a Co-Editor of the Industrial Biotechnology Journal.
About Dyadic
Dyadic International, Inc., is engaged in the development,
manufacture and sale of biological products (proteins, enzymes,
peptides and other bio-molecules), as well as the licensing of its
enabling proprietary technology to business collaborators for the
discovery, development and manufacture of biological products from
genes. Dyadic markets its products and services for applications in
the textile, chemical, agricultural, pulp & paper, pharmaceutical,
biotechnology and other industries, using its proprietary C1 Host
Technology and C1 Expression and Screening Systems for the discovery,
development and production of biological products.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are
"forward-looking statements." These forward-looking statements involve
risks and uncertainties that could cause our actual results,
performance or achievements to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. For a discussion of these risks and
uncertainties, please see our filings from time to time with the
Securities and Exchange Commission, which are available free of charge
on the SEC's web site at http://www.sec.gov, including our Annual
Report on Form 10-KSB for the year ended December 31, 2004, and our
Quarterly Report on Form 10-QSB for the quarter ended September 30,
2005. Except as required by law, we expressly disclaim any intent or
obligation to update any forward-looking statements.